
Virtue Insight
PRESENTS
PharmacoVigilance
UK & EU 2026
11 - 12 March 2026
Sheraton Skyline, Heathrow, London, UK

#VIphv

KEY SPEAKERS INCLUDE

HOWARD ABROMS
VP – Global Business Development
Soterius

GAYATHRI SUBBURAMAN
Senior Director, Global Safety Lead
Menarini Stemline

GALINA CORDERO
Head of Pharmacovigilance Dept, QPPV
JSC Farmak

PUNAM KUMARI
Founder & MD
Biovance Solutions

JOHN SOLOMON
Former Head of Pharmacovigilance - UK & Ireland, Sanofi

ABIDALI FAZAL
Safety Science Director
Roche

RACHEL MCDERMOTT
Senior Safety physician
Shionogi Europe

BEGUM BENLI PEKER
Head of Patient Safety EU Hub
Bristol-Myers Squibb

MARJAN DZEPAROSKI
Head of Regulatory Affairs, Drug Safety & Intelectual Property
Bionika Pharmaceuticals/UGD

TEA BABIC
Director, PV Audits & Inspections
Teva

SIMON ASHWORTH
Head of Pharmacovigilance & Medical Safety, MENARINI Group

SHIKTA DAS
Scientific Lead Real World Evidence, Oncology, AstraZeneca

TERESA SARAGOCA
Director, Regulatory Affairs & Technical Manager, ITALFARMACO

SUMIT MUNJAL
Global Head of Medical Safety
Otsuka Pharmaceuticals

RUDI SCHEERLINCK
Safety Strategy Lead – Oncology
Healthcare Business of Merck

SABINE POLTERMANN
Head of Country Patient Safety Switzerland
Bristol-Myers Squibb

PHILLIP EICHORN
Global Head of Drug Safety
Amryt Pharma

MICHAEL VON FORSTNER
Chief Scientific Officer
MedGenie

#VIphv

COMBINATION PRODUCTS

11:50 – Combination Products: Important Considerations for Patient Safety

- Medical Device Vigilance vs Pharmacovigilance
- Design Control
- Risk Management

JUDY BARRETTO
Senior Director, Virology TA, Patient Safety
Gilead Sciences

.....

12:20 – Adverse Drug Reactions in Special Populations: Insights from Pregnant Women and Children"

- Overview of physiological and pharmacokinetic differences influencing ADRs in pregnancy and pediatrics
- Common ADR patterns observed in these populations and real-world case insights
- Gaps in clinical trials and evidence generation for women and children
- Challenges in detection, dose adjustment, and safe prescribing
- Strategies to strengthen pharmacovigilance systems for vulnerable populations

REEM YASIN
Quality Assurance & PV Manager
Hawkary Pharmaceuticals

.....

12:40 – Networking luncheon

.....

RWD / RWE

13:40 – Panel Discussion: Harnessing RWD & RWE: Transforming the Future of Pharmacovigilance

Moderator

SANJEEV SRIVASTAV
Signal Management Lead
BioNTech

Panellists

RAGHDA MOHAMED
Patient Safety Cluster Lead - Middle East & Turkey / Global patient Safety Evaluation, Takeda Pharmaceuticals

SHIKTA DAS
Scientific Lead Real World Evidence, Oncology
AstraZeneca

GAYATHRI SUBBURAMAN
Senior Director, Global Safety Lead
Menarini Stemline

MAYUR PATEL
Head of Regulatory, Quality and Compliance | R&D Leader
PA Consulting

.....

REGULATORY

14:20 - Harmonizing Local PV Activity to Improve Efficiency" with the accent on non_EU Countries (Balkan).

MARJAN DZEPAROSKI
Head of Regulatory Affairs, Drug Safety & Intelectual Property, Bionika Pharmaceuticals/UGD

.....

14:40 – Panel Discussion: Regulatory Synergy in PV: Challenges, Opportunities & the Road Ahead

Moderator

PAV RISHIRAJ
Director, Pharmacovigilance & UK QPPV | ABPI PV Expert Chair, Ipsen

Panellists

STEPHANIE MILLICAN
Deputy Director BRE II
MHRA

MICHAEL BEAN
Senior Director, Regulatory Compliance
Johnson & Johnson

CALVIN JOHNSON
Vice President, International Patient Safety
Bristol-Myers Squibb